Denali Therapeutics Inc (DNLI) - Market Cap to Earnings
Denali Therapeutics (DNLI) is developing a unique method for drug delivery into the brain by collaborating with Western leaders under the protection of humanitarian status. The issuer's P/E ratio demonstrates the investment payback period, while the -9.50 metric indicates the status of the current valuation. However, dependence on Asian supplies and export restrictions could slow down global clinical trials of the software.
Comprehensive metric breakdowns and analytics for denalitherapeutics.com (DNLI)
- current price and projected stock value:
- market capitalization indicators:
- book value of equity indicators:
- company liabilities and liquidity data:
Debt to Equity Denali Therapeutics|DNLI - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Denali Therapeutics Inc.|DNLI - Company Total Debt|Debt to Net Assets Ratio Denali Corp|DNLI - Company Long-Term Liabilities|Amount of Current Liabilities Denali Therapeutics|Intermediate Coverage Ratio denalitherapeutics.com
- financial results and valuation multiples details:
DNLI - Net Profit|Expected Net Profit Denali Therapeutics|DNLI - Price to Earnings Ratio|Future Price to Earnings Multiple Denali Therapeutics Inc|DNLI - PEG Multiple|EV/EBITDA Multiple Denali Therapeutics Inc|DNLI - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Denali Therapeutics|DNLI - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months denalitherapeutics.com|DNLI - Net earnings per share growth this year|Earnings growth forecast for next year Denali Therapeutics
- company sales and revenue statistics:
General company analysis:Denali Therapeutics Inc - DNLI
Denali Therapeutics (DNLI) is building long-term patent potential through the development of innovative brain drug delivery methods, which the market is currently pricing into the stock. By analyzing the company's current P/E ratio, investors assess the relationship between market capitalization and actual earnings, allowing for a real-time assessment of the cost of capital and liquidity risks within the highly capital-intensive biotechnology sector.
Competing companies
Price to Earnings Ratio BIIB|P/E Multiple NBIX|Regencell (RGC) - Market Cap to Net Income Ratio|Price to Earnings Ratio axsome.com AXSM|P/E Multiple ACADIA Pharmaceuticals ACAD|XENE - Price to Earnings Ratio|Business Payback Period Viking Therapeutics Inc VKTX|Supernus Pharma (SUPN) - Price to Earnings Ratio|CPRX (Catalyst Pharmaceuticals) - Price to Earnings Ratio|Price to Earnings Ratio Harmony Biosciences Holdings, Inc.|Price to Earnings Ratio BHVN|Price to Earnings Ratio AMLX (Amylyx Pharmaceuticals, Inc.)|Market Price to Net Income Ratio TRVI|Price to Earnings Ratio Praxis Precision Medicines, Inc. PRAX|Anavex Corp - Price to Earnings Ratio|CBLL: Price to Earnings Ratio|Company Value to Net Income PRTA (prothena.com)|Alector, Inc. (ALEC) - Price to Earnings Ratio|Price to Earnings Multiple ANNX|Price to Earnings Ratio Omeros Corp.|Neurogene Therapeutics (NGNE) - Business Payback Period|P/E Multiple ACIU|VYGR (Voyager Therapeutics) - Company Value to Net Income|P/E Multiple NMRA (neumoratx.com)|SCLX: Price to Earnings Multiple|TVGN - Price to Earnings Ratio|Market Cap to Earnings Alpha Cognition Inc.|CGTX: P/E Multiple|inhibikase.com (IKT) - P/E Multiple|Price to Earnings Ratio Cassava Sciences Inc|ASRT - Market Cap to Net Income Ratio|Price to Earnings Ratio Coya (COYA)|P/E Multiple VistaGen Therapeutics Inc (VTGN)|Ovid Therapeutics Inc. - Price to Earnings Ratio|Business Payback Period Acumen Pharmaceuticals (ABOS)|CervoMed Corporation - P/E Multiple|Business Payback Period alteritytherapeutics.com ATHE|CLNN: P/E Multiple|Market Cap to Earnings PepGen Corp (PEPG)|Price to Earnings Ratio Jupiter Neurosciences, Inc.|RLMD: Company Value to Net Income|P/E Multiple ANVS|Price to Earnings Ratio Grace Tx GRCE|Price to Earnings Ratio Firefly Neuroscience, Inc AIFF|KLTO: Price to Earnings Multiple|NRSN - Price to Earnings Ratio|RVPH: Price to Earnings Ratio|MTVA (MetaVia Inc.) - Price to Earnings Ratio|NeurAxis Inc. (NRXS) - P/E Multiple|Price to Earnings Ratio Helius Medical|Passage Bio, Inc. - Market Cap to Net Income|Price to Earnings Ratio NEUP (Neuphoria)|NERV - Market Cap to Earnings|P/E Multiple ATHA (athira.com)|P/E Multiple Addex Therapeutics Ltd ADXN|Alzamend Neuro, Inc. - P/E Multiple|CYCN - P/E Multiple|PTIX (Protagenic Therapeutics, Inc.) - Price to Earnings Ratio|Market Cap to Earnings Pasithea (KTTA)|Price to Earnings Ratio Cortigent|Market Cap to Earnings Avenue Therapeutics Inc. ATXI|Price to Earnings Ratio brainstorm-cell.com (BCLI)|Price to Earnings Ratio Cara Therapeutics, Inc CARA|P/E Multiple CHRO (chromocell.com)|Company Value to Net Income ELYM|Intra-Cellular Therapies Inc. - P/E Multiple|Market Cap to Earnings Longboard Pharmaceuticals Inc|Marinus (MRNS) - Price to Earnings Ratio|NKGN - Business Payback Period|Price to Earnings Ratio NeuroBo Pharmaceuticals|SAGE: Company Value to Net Income|P/E Multiple SNPX|Trevena Inc. - Price to Earnings Multiple|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|Anew Medical, Inc. - Price to Earnings Ratio|Cerevel Therapeutics - P/E Multiple
